A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes in Chinese Population

Trial Identifier: D2287R00186
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: October 2026
Study Completion Date: October 2026
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Dongguan, China
China Foshan, China
China Guangzhou, China
China Hainan, China
China Hohhot, China
China Huizhou, China
China kunmin, China
China nanjing, China
China Nanning, China
China Shanghai, China
China Shenyang, China
China Taiyuan, China
China Wenzhou, China
China Wuhan, China
China Xi'an, China
China Xuzhou, China
China Zhanjiang, China
China Zhaoqing, China
China, Sichuan Chengdu, Sichuan, China